RxSight (RXST) 44th Annual J.P. Morgan Healthcare Conference summary

Business highlights and performance

• Achieved 12% year-over-year growth in procedures and nearly 20% increase in installed base for 2025.

• Fourth-quarter sales pre-announced at $32.6 million, surpassing expectations by about $5 million.

• Installed base now covers about 1,100 ophthalmic offices, with over 2,500 surgeons trained and 10–12% U.S. premium IOL market share.

• Announced new CFO, Mark Wilterding, bringing extensive MedTech and banking experience.

• Ended the year with approximately $225 million in cash, supporting future growth.

Market and technology overview

• Focused on premium intraocular lens (IOL) market, offering adjustable lenses that allow post-surgical customization.

• Adjustability enables patients to trial and personalize vision outcomes, leading to high refractive accuracy and satisfaction.

• About 40% of LAL patients would have otherwise received non-premium lenses, expanding the premium segment.

• Each LAL procedure generates about $2,000 in additional revenue for practices.

Growth strategy and operational changes

• Emphasis on increasing same-store sales and utilization within existing installed base.

• Organizational changes made to better align sales and clinical teams, improving customer support and adoption.

• Focused on leveraging learnings from early adopters to support newer customers and reduce workflow friction.

• Ongoing technical improvements, with over 40 PMA supplements introduced in five years.